TY - JOUR
T1 - Human papillomavirus antibodies and future risk of anogenital cancer
T2 - A nested case-control study in the European Prospective Investigation into Cancer and Nutrition study
AU - Kreimer, Aimée R.
AU - Brennan, Paul
AU - Lang Kuhs, Krystle A.
AU - Waterboer, Tim
AU - Clifford, Gary
AU - Franceschi, Silvia
AU - Michel, Angelika
AU - Willhauck-Fleckenstein, Martina
AU - Riboli, Elio
AU - Castellsagué, Xavier
AU - Hildesheim, Allan
AU - Fortner, Renée Turzanski
AU - Kaaks, Rudolf
AU - Palli, Domenico
AU - Ljuslinder, Ingrid
AU - Panico, Salvatore
AU - Clavel-Chapelon, Franc¸oise
AU - Boutron-Ruault, Marie Christine
AU - Mesrine, Sylvie
AU - Trichopoulou, Antonia
AU - Lagiou, Pagona
AU - Trichopoulos, Dimitrios
AU - Peeters, Petra H.
AU - Cross, Amanda J.
AU - Bueno-de-Mesquita, H. Bas
AU - Vineis, Paolo
AU - Larrañaga, Nerea
AU - Pala, Valeria
AU - Sánchez, María José
AU - Navarro, Carmen
AU - Barricarte, Aurelio
AU - Tumino, Rosario
AU - Khaw, Kay Tee
AU - Wareham, Nicholas
AU - Boeing, Heiner
AU - Steffen, Annika
AU - Travis, Ruth C.
AU - Quirós, J. Ramón
AU - Weiderpass, Elisabete
AU - Pawlita, Michael
AU - Johansson, Mattias
PY - 2015/3/10
Y1 - 2015/3/10
N2 - Purpose: Human papillomavirus (HPV) type 16 (HPV16) causes cancer at several anatomic sites. In the European Prospective Investigation Into Cancer and Nutrition study, HPV16 E6 seropositivity was present more than 10 years before oropharyngeal cancer diagnosis and was nearly absent in controls. The current study sought to evaluate the extent to which HPV16 E6 antibodies are present before diagnosis of anogenital cancers within the same cohort. Methods: Four hundred incident anogenital cancers (273 cervical, 24 anal, 67 vulvar, 12 vaginal, and 24 penile cancers) with prediagnostic blood samples (collected on average 3 and 8 years before diagnosis for cervix and noncervix cancers, respectively) and 718 matched controls were included. Plasma was analyzed for antibodies against HPV16 E6 and multiple other HPV proteins and genotypes and evaluated in relation to risk using unconditional logistic regression. Results: HPV16 E6 seropositivity was present in 29.2% of individuals (seven of 24 individuals) who later developed anal cancer compared with 0.6% of controls (four of 718 controls) who remained cancer free (odds ratio [OR], 75.9; 95% CI, 17.9 to 321). HPV16 E6 seropositivity was less common for cancers of the cervix (3.3%), vagina (8.3%), vulva (1.5%), and penis (8.3%). No associations were seen for non-type 16 HPV E6 antibodies, apart from anti-HPV58 E6 and anal cancer (OR, 6.8; 95% CI, 1.4 to 33.1). HPV16 E6 seropositivity tended to increase in blood samples drawn closer in time to cancer diagnosis. Conclusion: HPV16 E6 seropositivity is relatively common before diagnosis of anal cancer but rare for other HPV-related anogenital cancers.
AB - Purpose: Human papillomavirus (HPV) type 16 (HPV16) causes cancer at several anatomic sites. In the European Prospective Investigation Into Cancer and Nutrition study, HPV16 E6 seropositivity was present more than 10 years before oropharyngeal cancer diagnosis and was nearly absent in controls. The current study sought to evaluate the extent to which HPV16 E6 antibodies are present before diagnosis of anogenital cancers within the same cohort. Methods: Four hundred incident anogenital cancers (273 cervical, 24 anal, 67 vulvar, 12 vaginal, and 24 penile cancers) with prediagnostic blood samples (collected on average 3 and 8 years before diagnosis for cervix and noncervix cancers, respectively) and 718 matched controls were included. Plasma was analyzed for antibodies against HPV16 E6 and multiple other HPV proteins and genotypes and evaluated in relation to risk using unconditional logistic regression. Results: HPV16 E6 seropositivity was present in 29.2% of individuals (seven of 24 individuals) who later developed anal cancer compared with 0.6% of controls (four of 718 controls) who remained cancer free (odds ratio [OR], 75.9; 95% CI, 17.9 to 321). HPV16 E6 seropositivity was less common for cancers of the cervix (3.3%), vagina (8.3%), vulva (1.5%), and penis (8.3%). No associations were seen for non-type 16 HPV E6 antibodies, apart from anti-HPV58 E6 and anal cancer (OR, 6.8; 95% CI, 1.4 to 33.1). HPV16 E6 seropositivity tended to increase in blood samples drawn closer in time to cancer diagnosis. Conclusion: HPV16 E6 seropositivity is relatively common before diagnosis of anal cancer but rare for other HPV-related anogenital cancers.
UR - http://www.scopus.com/inward/record.url?scp=84924994015&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924994015&partnerID=8YFLogxK
U2 - 10.1200/JCO.2014.57.8435
DO - 10.1200/JCO.2014.57.8435
M3 - Article
C2 - 25667279
AN - SCOPUS:84924994015
VL - 33
SP - 877
EP - 884
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 8
ER -